Zusammenfassung
Einleitung Kopf-Hals-Tumoren und CUP-Syndrom zählen zu den dankbarsten Aufgaben der onkologischen PET/ CT-Diagnostik. Seit 1999 waren diese ein Präferenzkollektiv in Frankfurt/Main. In den Krebsstatistiken spiegelt sich ein kontinuierlicher Inzidenzanstieg wider. Zervikale Lymphknoten sind bevorzugter Drainageort von Metastasen. Für die Lokalisation von PET-Befunden sollte das Kompartimentmuster berücksichtigt werden (Tab. 9.1).
This is a preview of subscription content, log in via an institution.
Preview
Unable to display preview. Download preview PDF.
Literatur
Adamietz IA, Schemmann F, Baum RP, Knecht R, Saran F, Mose S, Thilmann C, Hör G, Böttcher HD (1995) Wertigkeit der SPECT-Immunszintigraphie für die Bestrahlungsplanung bei Patienten mit Plattenepithelkarzinomen im HNO-Bereich. Strahlenther Onkol 171: 278–283
Adams S, Baum RP, Hertel A, Schumm-Dräger PM, Usadel KH, Hör G (1996) Ganzkörper Fluor-18-Fluordeoxyglucose (FDG)-PET zum Nachweis okkulter metastasierter Schilddrüsenkarzinome. In: Reichwein D, Weinheimer B (Hrsg) De Gruyter, S 520–526
Adams S, Baum RP, Hertel A, Schumm-Dräger PM, Usadel KH, Hör G (1998) Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Eur J Nucl Med 25: 1277–1283
Adams S, Baum RP, Stuckensen T, Bitter K, Hör G (1998) Prospective comparison of FDG PET with conventional imaging modalities CT, MRI, US in lymph node staging of head and neck cancer. Eur J Nucl Med 25: 1255–1260
Adams S, Nickel E, Hör G (2000) Differentialdiagnostische Problematik bei der Beurteilung von mediastinalen und pulmonalen Herden mittels F-18-FDG (Kasuistik). Nuklearmedizin 5: N83–N84
Adams S, Acker P, Lorenz M, Staib-Sebler E, Hör G (2001) Radioisotope-guided surgery in patients with pheochromocytoma and recurrent medullary thyroid carcinoma. Cancer 92: 263–270
Adams S, Baum RP, Knecht R, Hör G (2001) Staging und Rezidivdiagnostik von Tumoren im Kopf-Hals-Bereich. Der Nuklearmediziner 24: 47–54
Alkureishi LWT, Burak Z, Alvarez JA et al. (2009) Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging 37: 1915
Allal AS, Dulguerov P, Allaoua M, al (2002) Standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 42: 1398–1404
Avril N, Dose J, Jänicke F, Ziegler S et al. (1996) Assessment of axillary lymphnode involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Nat Cancer Inst 88: 1204–1209
Bar-Shalom R, Gaitini D, Keidar Z, Israel O (2004) Non-malignant FDG uptake in infradiaphragmatic adipose tissue: a new site of physiological tracer biodistribution charcterized by PET/CT. Eur J Nucl Med Mol Imaging 31: 1105–1113
Behr TM, Gratz S, Herrmann A et al. (1997) Anti-CEA-Antikörper versus Somatostatin-Analoga zur Detektion metastasierter medullärer Schilddrüsen-Karzinome: Sind CEA- und Somatostatin-Rezeptor-Expression prognostische Faktoren? Nuklearmedizin 36: A62
Belhocine T, Blockmans D, Hustinx R et al. (2003) Imaging of large vessel vasculitis with (18)FDG PET. Illusion or reality? A critical review. Eur J Nucl Med 30: 1305–1313
Blumstein NM, Reske SN (2004) PET und PET/CT bei Kopf-Hals-Tumoren. Der Nuklearmediziner 27: 260–271
Branstetter BF, Blodgett TM, Zimmer LA et al. (2005) Head and neck malignancy: Is PET/CT more accurate than PET or CT alone? Radiology 235: 580–586
Charron M, Beyer Th, Bohnen NN et al. (2000) Image analysis in patients with cancer studied with a combined PET and CT scanner. Lippincott Williams & Wilkins, Philadelphia, S 905–910
Chen Y, Su C, Ding H et al. (2006) Clinical usefulness of fused PET/CT compared with PET alone or CT alone in nasopharyngeal carcinoma patients. Anticancer Res 26: 1471–1477
Chung J (2002) Sodium iodide symporter: Its role in Nuclear Medicine. J Nucl Med 43: 1188–1200
Chung JK, Kang JH (2004) Translational research using the sodium/iodide symporter in imaging and therapy. Eur J Nucl Med Mol Imaging 31: 799–802
Cobben DC, van der Laan BF, Hoekstra HJ et al. (2002) Detection of mammary, laryngeal and soft tissue tumors with FLT-PET. J Nucl Med 43: P278
Dai G, Levy O, Carrasco N (1996) Cloning and characterization of the thyroid iodide transporter. Nature 379: 458–460
Davies JR, Rudd JH, Weissberg PL (2004) Molecular and metabolic imaging of atherosclerosis. J Nucl Med 45: 1898–1907
Delgado-Bolton RC, Fernández-Pérez C et al. (2003) Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med 44: 1301–1314
Deutsche Krebsgesellschaft (2002) Kurzgefaßte Interdisziplinäre Leitlinien. 3. Auflage
Erdi YE, Larson SM (2002) PET/CT scanners improve cancer treatment planning. Diagnostic Imaging Nov: 11–12
Fischbein NJ, Novorolski SM, Henry RG et al. (2003) Assessment of metastatic cervical adenopathy using dynamic contrast-enhanced MR imaging. AJNR Am J Neuroradiol 24: 301–311
Flower MA, Al-Saadi A, Harmer CL, McCready VR, Ott RJ (1994) Dose-response study on thyrotoxic patients undergoing positron emission tomography and radioiodine therapy. Eur J Nucl Med 21: 531–536
Gabriel M, Decristoforo C, Kendler D et al. (2007) 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48: 508–518
Gitsch E (1970) Die Radioisotopenoperation in der Gynäkologie. Wiener Klin Woch 42/43: 727–730
Goerres GW, von Schulthess GK, Hany TF (2002) Positron Emission Tomography and PET CT of the head and neck: FDG uptake in normal anatomy, in benign lesions, and in changes resulting from treatment. Am J Roentgenol 179: 1337–1343
Goerres GW, von Schulthess GK, Steinert HC (2004) Why most PET of lung and head neck cancer will be PET/CT. J Nucl Med 45 (Suppl 1): 66S–71S
Goerres GW, Schmid DT, Schuknecht B, Eyrich GK (2005) Bone invasion in patients with oral cavity cancer: comparison of conventional CT with PET/CT and SPECT/CT. Radiology 237: 281–287
Gordin A, Daitzchman M, Doweck I et al. (2006) Fluordeoxyglucose positron emission tomography/computed tomography imaging in patients with carcinoma of the larynx: diagnostic accuracy and impact on clinical management. Laryngoscope 116: 273–278
Haberkorn U, Strauss LG, Reisser Chet al. (1991) Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med 32: 1548–1555
Hauth E, Antoch G, Freudenberg LS et al. (2003) Einsatz der PETCT und Ganzkörper-MRT bei Patienten mit Karzinom ohne gesicherten Primärtumor (CUP-Syndrom). Fortschr Röntgenstr. http://www.thieme.de/roefo/abs
Heath JR, Phelps ME, Hood L (2003) Nano systems biology. Mol Imaging Biol 5: 312–325
Heufelder AE, Joba W (2001) Der Natrium-Jodid-Symporter in der Diagnostik und Therapie von Schilddrüsenerkrankungen. Der Nuklearmediziner 24: 117–127
Hilson AWJ, Lewis CA (1991) Radionuclide studies in impotence. Semin Nucl Med 21: 159–164
Hör G, Maul FD, Standke R, Munz D (1981) Scintigraphy in oncology-review on present, outlook on further possibilities: 201 TlCl. IAEA, Vienna, S 487–495
Ito S, Kato K, Ikeda M et al. (2007) Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. J Nucl Med 48: 889–885
Jemal A, Murray T, Ward E (2005) Cancer Statistics 2005. CA Cancer J Clin 55: 10–30
Kim H, Boyd J, Dunphy F, Lowe V (1998) F-18 FDG PET scan after radiotherapy for early-stage larynx cancer. Clin Nucl Med 11: 750–752
Kim SY, Roh J, Kim M et al. (2007) Use of 18F-FDG for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med 48: 752–757
Kluetz PG, Meltzer CC, Villemagne VL et al. (2000) Combined PET/CT imaging in oncology: impact on patient management. Clin Positron Imag 3: 223–230
Kouvaraki MA, Shapiro SE, Fornage BD et al. (2003) Role of preoperative ultrasonography in surgical management of patients with thyroid cancer. Surgery 134: 946–954
Lan X, Zhang Y, Tan X et al. (2009) Role of 18F-FDG PET/CT in following-up patients with nasopharyngeal carcinoma after therapy. Springer Berlin: 0P371, S229
Lardinois D, Weder W, Hany TF et al. (2003) Staging of nonsmall cell lung cancer with integrated positron emission tomography and computed tomography. N Engl J Med 348: 2500– 2507
Lowe VJ, Kim H, Boyd JH et al. (1999) Primary and recurrent early stage laryngeal cancer: preliminary results of 2-[fluorine 18]fluoro-2-deoxy-D-glucose PET imaging. Radiology 212: 799–802
Lowe VJ, Boyd JH, Dunohy FR et al. (2000) Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 18: 651–658
Mazzaferri EL (2005) Empirically treating high serum thyreoglobulin levels. J Nucl Med 46: 1079–1088
Mazzaferri EL, Kloos RT (2002) Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 87: 1490–1498
Miehel K, Paschke R (2004) Molekulargenetik und molekulare Diagnostik bei Schilddrüsenerkankungen. Nuklearmediziner 27: 120–122
Minn H, Paul R, Ahonen A (1988) Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med 29: 1521–1525
Muhle C, Brenner W, Südmeyer M et al. (2004) CT-guided lymphoscintigraphy in patients with squamous cell carcinoma of the head and neck: a feasibility study. Eur J Nucl Med Mol Imaging 31: 940–944
Munz DL (2001) The sentinel lymph node concept in oncology. Zuckschwerdt, München
Munz DL, Maza S, Ivancevic V, Geworski L (2000) Classification of the lymphatic drainage status of a primary tumor: a proposal. Nuklearmedizin 39: 88–91
Nakamoto Y, Tatsumi M, Hammoud D et al. (2005) Normal FDG distribution pattern in head and neck: PET/CT evaluation. Radiology 234: 879–885
Ng SH, Chang JT, Chan S et al. (2004) Nodal metastases of nasopharyngeal carcinoma: patterns of disease on MRI and FDG PET. Eur J Nucl Med Mol Imaging 31: 1073–1180
Ng SH, Yen TC, Liao CT et al. (2005) 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. J Nucl Med 46: 1136– 1143
Niu G, Gaut AW, Boles Ponto LL et al. (2004) Multimodality noninvasive imaging of gene transfer using the human sodium iodide symporter. J Nucl Med 43: 445–449
Oehler W, Baum RP (2004) Aktueller Beitrag der PET und PET/CT zur Zielvolumenmodulation für die biologisch-medizinische Planung im Rahmen der intensitätsmodulierten Strahlentherapie (IMRT). Der Nuklearmediziner 27: 324–329
Ott RJ, Batty V, Webb S, Flower MA et al. (1987) Measurement of radiation dose to the thyroid using positron emission tomography. J Radiol 60: 245–251
Pauleit D, Zimmermann A, Stoffels G et al. (2006) 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer. J Nucl Med 47: 256–261
Paulus P, Sambon A, Vivegnis D et al. (1998) 18F-FDG PET for the assessment of primary head and neck tumors: clinical, computed tomography, and histopathological correlation in 38 patients. Laryngoscope 108: 578–583
Regelink G, Brouwer J, de Bree R et al. (2002) Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur J Nucl Med 29: 1024–1030
Reiser M, Kuhn FP, Debus J (2004) Radiologie. Thieme, Stuttgart
Reske S, Kotzerke J (2001) FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, »Onko-PET III«, 21 July and 19 September 2000. Eur J Nucl Med 28: 1707– 1723
Riede UN, Schäfer HE (1999) Allgemeine und Spezielle Pathologie. Thieme, Stuttgart
Ringel MD, Balducci-Silano PL, Anderson JS et al. (1999) Quantitative reverse transscription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma. J Clin Endocrinol Metabol 84: 4037–4042
Rosenbaum S, Freudenberg L, Pink R et al. (2004) PET/CT-Stellenwert beim Schilddrüsenkarzinom. Der Nuklearmediziner 27: 272–277
Schlüter B, Bohuslavizki KH, Beyer W et al. (2001) Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 42: 71–76
Schmidt D, Herzog H, Langen KJ, Müller-Gärtner HW (1994) Glucose metabolism in thyroid cancer metastases. Exp Clin Endocrinol 102: 51–54
Schöder H, Yeung HW (2004) Positron emission of head and neck cancer, including thyroid carcinoma. Semin Nucl Med 34: 180– 197
Schöder H, Carlson DL, Kraus DH et al. (2006) 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med 47: 755–762
Schönberger J, Ruschoff J, Grimm D et al. (2002) Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid 12: 747–754
Shah JP (1990) Patterns of cervical lymphnode metastasis from squamous carcinomas of the upper aerodistive tract. Am J Surg 160: 405–409
Shu-Hang N, Chang J, Tung-Chieh JC et al. (2004) Clinical usefulness of 18F-FDG PET in nasopharyngeal carcinoma patients with questionable MRI findings for recurrence. J Nucl Med 45: 1669– 1676
Steinkamp HJ, Hosten N, Langer R, Mathe F, Ehritt C, Felix R (1992) Halslymphknotenmetastasen. Sonographischer Malignitätsnachweis. Fortschr Röntgenstr 156: 135–141
Stuckensen T, Kovacs AF, Adams ST, Baum RP (2000) Staging of the neck in patients with oral cavity squamous cell carcinoma: a prospective comparison of PET, ultrasound, CT and MRI. J Craniomaxillofac Surg 28: 319–324
Sundaresan G, Yazaki PJ, Shively JE et al. (2003) 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 44: 1962–1969
Teixeira JPVP, Duarte H, Lucena I et al. (2009) Clinical significance of incidental thyroid findings on 18F-FDG PET/CT. Springer, Berlin: 0P602, S274
Torabi M, Aquino SL, Harisinghani M (2004) Current concepts in lymph node imaging. J Nucl Med 45: 1509–1518
Troost EGC, Vogel WV, Merkx MAW et al. (2007) 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med 48: 726
Vogl T, Mees K, Muhlig M, Lissner J (1987) Magnetic resonance imaging in diagnosing diseases of the neck. Hospimedica 5: 1–2, 17
Vogl TJ, Grevers G, Lissner J (1992) Die Magnetresonanzverfahren für die Tumordiagnostik in der Kopf-Hals-Region. Dtsch Ärztebl 89: B-2539–B-2546
Wang W, Larson SM, Tuttle RM et al. (2001) Resistence of [18f ]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 11: 1169–1176
Wax MK, L Myers L, Gubulski EC et al. (2002) Positron emission tomography in the evaluation of synchronous lung lesions in patients with untreated head and neck cancer. Arch Otolaryngol Head Neck Surg 28: 703–707
Weissleder R, Elizondo G, Wittenberg J et al. (1990) Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 175: 489–493
Yasuda S, Shotsu A, Ide M et al. (2007) Chronic thyreoiditis: diffuse uptake of FDG at PET. Radiology: 775–778
Yau K, Price P, Pillai RG, Aboagye E (2006) Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidilate synthase inhibitors. Eur J Nucl Med Mol Imaging 33: 981–987
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Mohnike, W., Hör, G., Schelbert, H. (2011). Kopf-Hals-Region. In: PET/CT-Atlas. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-17805-4_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-17805-4_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-17804-7
Online ISBN: 978-3-642-17805-4
eBook Packages: Medicine (German Language)